NPC Study Says New Drugs Offset Nondrug Spending: Will CBO Agree?
Executive Summary
A National Pharmaceutical Council-funded analysis of the value of newer medicines will give brand name pharmaceutical companies additional evidence to argue that the cost of a Medicare prescription drug benefit may be offset by savings in other health spending.
You may also be interested in...
Milken Institute Center To Study FDA Approval Process, Innovation Strategies
The Milken Institute's Center for Accelerating Medical Solutions hopes to begin operations in Washington, D.C. during the summer
FDA “Strategic Plan” Team Takes Shape: McClellan Names Senior Advisors
FDA Senior Economic Advisor Tomas Philipson, PhD, will work with Commissioner Mark McClellan, MD/PhD, to develop strategic initiatives
Milken Institute Center To Study FDA Approval Process, Innovation Strategies
The Milken Institute's Center for Accelerating Medical Solutions hopes to begin operations in Washington, D.C. during the summer